Omiloxetine Explained

Omiloxetine (omiloextinum, omiloxetino INN)[1] was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2] [3]

Rafael Foguet also patented Abaperidone.

Notes and References

  1. WHO Drug Information . 10 . 4 . 212–213 . 1996 . Proposed INN: List 76 .
  2. Web site: Omiloxetine - Ferrer licensing offer, worldwide . https://web.archive.org/web/20160307142131/https://business.highbeam.com/436989/article-1G1-139327925/omiloxetine-ferrer-licensing-offer-worldwide . dead . 2016-03-07 . Terencio J . R & D Focus Drug News . 2005-12-05 . 2012-05-19.
  3. Web site: Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data . https://web.archive.org/web/20160307095303/https://business.highbeam.com/436989/article-1G1-110935603/omiloxetine-ferrer-partnering-opportunity-worldwide . dead . 2016-03-07 . De Lecea C . R & D Focus Drug News . 2003-12-08 . 2012-05-19.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Omiloxetine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.